Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989)
:9989
Want to see HK:9989 full AI Analyst Report?
Top Page
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
(9989)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$5.00
▼(-3.66% Downside)
Action:ReiteratedDate:05/02/26
The score is driven primarily by stable-to-improving financial health (profitability recovery, strong cash conversion, moderate leverage) and supportive valuation (low P/E and high dividend yield). These positives are tempered by weak technicals showing a clear downtrend and bearish momentum, alongside flat revenue and reduced profitability versus 2024.
Positive Factors
Free Cash Flow Quality
Sustained free cash flow that closely tracks net income indicates high earnings quality and strong cash conversion. Over a 2–6 month horizon this supports dividend capacity, debt servicing, and reinvestment in R&D or capacity, giving the company financial flexibility through cycles.
Negative Factors
Flat Revenue Growth
Stagnant top-line growth limits the firm's ability to scale fixed-cost recovery and improve margins. Without clear secular revenue expansion, profitability gains must come from cost cuts or mix shift, increasing execution risk and constraining longer-term return improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Free Cash Flow Quality
Sustained free cash flow that closely tracks net income indicates high earnings quality and strong cash conversion. Over a 2–6 month horizon this supports dividend capacity, debt servicing, and reinvestment in R&D or capacity, giving the company financial flexibility through cycles.
Read all positive factors
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$16.60B
Dividend Yield5.23%
Average Volume (3M)1.16M
Price to Earnings (P/E)8.4
Beta (1Y)0.92
Revenue Growth3.74%
EPS Growth-40.22%
CountryHK
Employees1,926
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.26
Shares Outstanding220,094,500
10 Day Avg. Volume947,650
30 Day Avg. Volume1,161,300
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)0.57
Price to Sales (P/S)1.25
P/FCF Ratio4.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.54
Revenue Forecast (FY)HK$6.73B
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose...
How the Company Makes Money
Hepalink primarily makes money by selling pharmaceutical products and services across several revenue streams: (1) Sales of heparin-based APIs: The company manufactures heparin and low-molecular-weight heparin (LMWH) APIs used by other pharmaceuti...
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
72
Positive
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.42B | 5.48B | 5.28B | 5.45B | 7.16B | 6.37B |
| Gross Profit | 1.82B | 1.74B | 1.76B | 1.80B | 2.33B | 2.03B |
| EBITDA | 455.44M | 846.59M | 1.20B | ― | 1.37B | 726.64M |
| Net Income | 380.42M | 349.49M | 646.74M | ― | 727.43M | 240.79M |
Balance Sheet | ||||||
| Total Assets | 17.01B | 16.63B | 17.34B | 19.20B | 20.81B | 19.11B |
| Cash, Cash Equivalents and Short-Term Investments | 3.50B | 2.83B | 2.56B | 2.27B | 3.45B | 3.93B |
| Total Debt | 2.79B | 2.11B | 2.98B | 3.78B | 6.46B | 5.65B |
| Total Liabilities | 4.78B | 4.55B | 5.14B | 7.22B | 8.41B | 7.58B |
| Stockholders Equity | 12.18B | 12.03B | 12.15B | 11.91B | 12.31B | 11.41B |
Cash Flow | ||||||
| Free Cash Flow | 1.46B | 1.59B | 1.99B | -46.66M | -979.03M | -200.49M |
| Operating Cash Flow | 1.57B | 1.71B | 2.19B | 398.22M | -756.61M | -6.63M |
| Investing Cash Flow | -830.83M | -872.75M | -415.05M | 1.22B | 249.84M | 719.93M |
| Financing Cash Flow | -853.95M | -1.09B | -2.14B | -1.21B | 329.56M | -501.08M |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Technical Analysis
Negative
5.19
Price Trends
5.19
Negative
5.24
Negative
5.55
Negative
Market Momentum
-0.04
Negative
40.56
Neutral
39.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9989, the sentiment is Negative. The current price of 5.19 is above the 20-day moving average (MA) of 4.98, below the 50-day MA of 5.19, and below the 200-day MA of 5.55, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 40.56 is Neutral, neither overbought nor oversold. The STOCH value of 39.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9989.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | HK$16.60B | 8.36 | 2.86% | 5.23% | 3.74% | -40.22% | |
58 Neutral | HK$70.96B | 13.21 | 7.02% | 1.69% | 1.52% | 22.54% | |
58 Neutral | HK$32.42B | 3.24 | 7.91% | 2.95% | 4.66% | 20.77% | |
55 Neutral | HK$18.35B | ― | 41.38% | ― | -13.04% | 1113.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | HK$11.94B | -42.31 | -0.02% | ― | 31.39% | 98.96% |
* Healthcare Sector Average
HK:9989
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
4.81
0.52
12.12%
HK:0013
HUTCHMED (China)
21.04
-2.96
-12.33%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
19.13
5.63
41.75%
HK:3320
China Resources Pharmaceutical Group Ltd.
5.16
0.39
8.22%
HK:6185
CanSino Biologics, Inc. Class H
29.20
-3.80
-11.52%
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Corporate Events
Hepalink Files Unaudited First-Quarter 2026 Report With Full Board Approval
Apr 29, 2026
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., a Hong Kong-listed PRC pharmaceutical group, has released its unaudited financial results for the first quarter of 2026, prepared under Chinese accounting standards. The company’s board and s...
Hepalink Sets 2025 AGM to Decide Profit Distribution, Board Mandates and Capital Management
Apr 29, 2026
Shenzhen Hepalink Pharmaceutical Group has convened its 2025 annual general meeting for May 22, 2026 in Shenzhen, where shareholders will review the 2025 audited financial statements, decide on the profit distribution proposal, confirm directors&#...
Shenzhen Hepalink Sets Board Meeting to Approve Q1 2026 Results
Apr 17, 2026
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has scheduled a board meeting for April 29, 2026 to review and approve its first-quarter results for the period ended March 31, 2026. The announcement signals that the company is preparing to releas...
Shenzhen Hepalink Clarifies 2025 Final Dividend Terms and Record Dates
Mar 31, 2026
Shenzhen Hepalink Pharmaceutical Group has clarified details of its proposed final dividend for 2025, confirming a distribution of RMB1.45 per ten ordinary shares, subject to shareholder approval at the annual general meeting on May 22, 2026. The ...
Shenzhen Hepalink Announces Proposed Final Dividend for FY2025
Mar 30, 2026
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has proposed a final ordinary cash dividend of RMB 1.45 per 10 shares for the financial year ended 31 December 2025, subject to shareholder approval at a meeting scheduled for 22 May 2026. The divid...
Hepalink 2025 Profit Falls on API Weakness Despite Modest Revenue Growth
Mar 30, 2026
Shenzhen Hepalink Pharmaceutical Group reported 2025 revenue of RMB5.44 billion, up slightly from a year earlier, with growth driven mainly by its finished dose pharmaceutical products business, whose sales rose to RMB3.50 billion and achieved a h...
Shenzhen Hepalink Sets March 30 Board Meeting to Approve 2025 Results and Weigh Dividend
Mar 16, 2026
Shenzhen Hepalink Pharmaceutical Group has scheduled a board meeting for March 30, 2026, to review and approve its annual results for the year ended December 31, 2025, and to authorize their publication. The board will also consider whether to rec...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.